Tfelt-Hansen, Peer C <br/><br/>
Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment.  [electronic resource] 

 -  The journal of headache and pain  Dec 2009 
 - 389-91 p.  digital 
<br/><br/> Publication Type: Editorial 
<br/><br/><label>ISSN: </label>1129-2377 
<br/><br/><label>Standard No.: </label>10.1007/s10194-009-0157-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Azepines--pharmacology<br/>Calcitonin Gene-Related Peptide--metabolism<br/>Calcitonin Gene-Related Peptide Receptor Antagonists<br/>Cerebral Arteries--drug effects<br/>Clinical Trials as Topic<br/>Dipeptides--pharmacology<br/>Humans<br/>Imidazoles--pharmacology<br/>Migraine Disorders--drug therapy<br/>Piperazines<br/>Quinazolines--pharmacology<br/>Receptors, Calcitonin Gene-Related Peptide--metabolism<br/>Serotonin Receptor Agonists--pharmacology<br/>Treatment Failure<br/>Tryptamines--pharmacology